Los Angeles, January 5th 2018
FLUIDDA Inc and the University of California, San Francisco (UCSF) are entering into a new research collaboration as of December 2017. Together with the team of Dr. John Fahy (Professor of Medicine in the Division of Pulmonary and Critical Care Medicine, Department of Medicine and investigator in the Cardiovascular Research Institute), FLUIDDA will engage in a project exploring the effects of pathologic mucus gels in lung disease. Dr. Fahy directs a translational research program in asthma and other airway diseases that aims to uncover fundamental disease mechanisms and improve patient treatment. FLUIDDA will apply its innovative computational techniques to understand the effects of pathologic mucus on lung function and on the deposition patterns of inhaled therapeutics.
Dr. Jan De Backer, FLUIDDA’s CEO, commented “We are very excited to embark upon this collaboration with the renowned group of Dr. Fahy. Using our imaging technology to understand the role of mucus in the disease process of asthmatic patients is a challenging but highly interesting topic. Together we believe we can make significant progress in the development of better therapies for patients suffering from lung diseases.”